Picici direct Research

CMP: ₹ 673

Target: ₹ 730 (9%) Target Period: 12 months

HOLD

November 4, 2020

Recovery on fast track; upbeat outlook ahead...

Varun Beverages reported strong Q3CY20 results with 3.6% revenue growth given beverage remains largely an out of home consumption category. Volume were down 4% to 119 million (mn) cases with India business volume down 6.7% and international business seeing volume growth of 5.8%. Realisation increased 8%, mainly on the back of a cut in trade promotions and mix change in favour of carbonated soft drinks (CSD) Despite hotel, restaurants & cafes remaining closed, the company was able to restrict volume de-growth to single digits. India business growth of 12.9% in September month is also a sign of normalised growth. Gross margins contracted 149 bps mainly due to increase in sales of consumer promotional packs. However, a 50 bps saving in employee spends to sales & 343 bps savings in overhead spends to sales resulted in operating profit increase of 16.9% to ₹ 380.8 crore. Operating margins expanded 241 bps to 21.1%. Interest cost declined 33.2% to ₹ 58 crore mainly due to repayment of debt with QIP proceeds in September 2019 and reduction in cost of debt to 7%. This resulted in a robust jump in net profit by 99% to ₹ 161.5 crore.

Beverage segment to see full recovery in CY21

With 12.9% growth in September, the impact of lockdown and restricted out-of-home consumption seems to have been largely recovered. July & August volume were down 20% & 6%, respectively. With the 'on the go' & 'out of home' consumption impacted during Covid times, VBL has been focusing on increasing 'at-home' consumption. It has launched 1.25 litre pack at ₹ 50, which is largely driving 'at-home' consumption. We believe CY21 would be a normalised year given lockdown restrictions would be completely lifted (multiplex, restaurants, hotels, café operations are largely expected to normalise). We expect 6.1% revenue CAGR in CY19-22E largely with 21% growth recovery in CY21.

Benign commodity prices, cost rationalisation to aid margins

With a sharp fall in PET resin prices & stable sugar price, we expect gross margin expansion of 72 bps in CY21. Moreover, cost rationalisation measure would lead to operating margin expansion of 124 bps in CY21. VBL expects these cost cutting measure to remain permanent. The management has guided 21% operating margin for CY21. Further, we believe juices & CSD contribution would increase, going forward, as the company would be able to generate more margin considering its new Juice plant has already been commissioned. VBL would be re-launching milk based beverages in CY21 as launch in CY20 could not see much uptick due to lockdown.

Valuation & Outlook

Source: Company, ICICI Direct Research


Carbonated drinks, juices & water businesses are discretionary in nature with ~70% of sales contributed by 'on the go' consumptions with a single serve pack selling the most. With a significant reduction in 'out of home' category, the company has been able to recoup its volume by focusing on increasing 'at-home' consumption. We expect the full recovery to happen only in CY21 with sales surpassing CY19 levels. We value the stock at 14x CY22 EV/EBITDA with a revised target price of ₹ 730/share and HOLD rating.



Particulars	
Particulars (₹ crore)	Amount
Market Capitalization	19,428.7
Total Debt (CY19)	2,822.5
Cash & Investments (CY19)	171.1
EV	22,080.2
52 week H/L (₹)	869 / 486
Equity capital	288.7
Face value	10.0

Key Highlights

- Total sales volumes down 4% to 119 million cases. Realisation up 8% mainly due to cut in promotions & change in mix
- Operating margins expand 240 bps with various cost rationalisation measures in place
- Maintain HOLD rating with revised target price of ₹ 730/share



Research Analyst

Sanjay Manyal

sanjay.manyal@icicisecurities.com

Key Financials	CY18	CY19	CY20E	CY21E	CY22E	CAGR (CY19-22E)
Net Sales	5105.3	7129.6	6395.0	7753.0	8513.4	6.1%
EBITDA	1006.6	1447.7	1208.9	1562.3	1709.3	5.7%
EBITDA Margin %	19.7	20.3	18.9	20.2	20.1	
Net Profit	299.9	472.2	326.5	627.1	768.0	17.6%
EPS (₹)	16.42	16.36	11.31	21.72	26.60	
P/E	41.0	41.1	59.5	31.0	25.3	
RoNW %	15.0	14.2	10.1	16.7	17.6	
RoCE (%)	14.2	15.5	12.3	18.6	20.7	

CICI Securities – Retail Equity Research

Result Update

Particulars (₹ crore)	Q3CY20	Q3CY19	YoY (%)	Q2CY20	QoQ (%)	Comments
Net Sales	1,802.6	1,739.7	3.6	1,640.2	9.9	Net sales grew 3.6% on the back of 8% realisation growth and 4% volume decline
Raw Material Expenses	801.0	747.2	7.2	741.1	8.1	Gross margins contracted 150 bps mainly due to cut in promotional spends
Employee Expenses	229.6	229.6	0.0	199.3	15.2	
Other operating Expenses	391.3	437.3	-10.5	322.1	21.5	The company took cost rationalisation measures, which resulted in 10% decline in overhead costs
EBITDA	380.8	325.7	16.9	377.7	0.8	
EBITDA Margin (%)	21.1	18.7	241 bps	23.0	-190 bps	Operating margins improved 240 bps despite gross margin contraction, mainly due to cost cutting measures
Depreciation	134.6	127.3	5.7	124.3	8.3	
Interest	58.0	86.7	-33.2	74.2	-21.9	Significant decline in interest cost due to repayment of debt from funds raised by QIP & lower interest cost at 7%
Other Income	3.5	1.8	92.8	2.7	30.6	
PBT	191.7	113.4	69.1	181.9	5.4	
Exceptional Items	0.0	0.0		0.0		
Tax Outgo	30.2	34.5	-12.4	38.9	-22.2	
PAT	161.5	81.1	99.0	143.0	12.9	With strong operating profit & lower interest cost, net profit increase 99% to ₹ 161.5 crore
Adj. PAT	161.5	81.1	99.0	143.0	12.9	

Source: Company, ICICI Direct Research

Exhibit 2: (Change i	in estima	ates					
		CY20E			CY21E		CY22E	
(₹ Crore)	Old	New	% Change	Old	New	% Change	New	Comments
Net Sales	6,053.3	6,395.0	5.6	7,336.9	7,753.0	5.7	8,513.4	We increased our sales & margins estimates after stronger results in Q3. We introduce CY22 numbers
EBITDA	1,107.0	1,208.9	9.2	1,430.7	1,562.3	9.2	1,709.3	
EBITDA Margin(%)	18.3	18.9	62 bps	19.5	20.2	65 bps	20.1	
PAT	281.1	326.5	16.1	531.1	627.1	18.1	768.0	
EPS (₹)	9.74	11.31	16.1	18.40	21.72	18.1	-26.6	

Source: Company, ICICI Direct Research

			Current				Earl	lier	
Particulars (in million cases)	CY17	CY18	CY19E	CY20E	CY21E	CY22	CY20E	CY21E	Comments
Carbonated Products	220.0	257.0	388.1	345.4	414.5	443.5	322.1	386.5	We change our sales estimates mainly on account of better-than-expected recovery in Q3. We introduce CY22 numbers
% Growth	-1.3	16.8	51.0	-11.0	20.0	7.0	-17.0	20.0	
Non Carbonated Products	14.0	22.0	29.7	28.2	33.3	35.3	28.2	33.3	
% growth	-11.1	57.1	35.0	-5.0	18.0	6.0	-5.0	18.0	
Raw Material Cost									
Sugar	616.6	698.4	1,086.0	922.6	1,114.6	1,251.3	865.1	1,045.0	
% of sales	13.4	14.2	15.1	14.1	14.1	14.5	14.0	13.9	
cost/kg (₹)	38.9	37.0	36.6	34.8	36.5	38.4	34.8	36.5	

Conference Call Highlights

- Revenues witnessed growth of 3.8% led by 8% realisation growth due to a cut in trade promotions spends & change in product mix in favour of carbonated soft drinks (CSD). Volumes were down 4% due to 6.7% volume decline in India business and 5.5% growth in international business
- The recovery in the growth was largely contributed by rural & semiurban territories. Moreover, the company pushed 'at-home' consumption with the launch of 1.25 litre pack at ₹ 50. The management said the growth in 'at-home' consumption is ~25%
- Volume declined 4% to 119 mn cases. Out of this, 74% was contributed by CSD whereas juices & water categories contributed 6% & 24%, respectively
- The company recorded 20% & 6% decline in July & August sales, respectively, whereas September sales were up 12.9% with out of home activity starting to normalise to pre-Covid levels. With the resumption of multiplexes, hotels, cafes & restaurant operations, we believe CY21 would be a normalised year from both demand & supply side
- The company expects to clock operating margins of 21%, going forward, given PET resin prices are down, sugar prices are stable and the company has rationalised many overhead costs
- VBL would look to kick-start the next season activation earlier than usual with the joint strategy adopted by Pepsi and VBL
- Rural & semi-urban sales contribute ~30-40% of overall sales. Institutional sales contribute 2-3% to revenues
- The company would be installing, on an average, 40,000 visi coolers. CY20 has seen a slower installation of visi coolers due to Covid. However, the gap will be made up by putting up additional coolers in CY21
- VBL would be commissioning a Tropicana plant in South India, which would aid juices volumes, going forward. The company is currently witnessing 19% growth in the juices segment
- The debt levels are currently at ₹ 2830 crore. Cash profit in nine months was a ₹ 750 crore with capex of ₹ 400 crore. Free cash flow in nine months has been ₹ 350 crore
- Free cash has been utilised as ₹ 100 crore debt reduction, ₹ 85-90 crore dividend payment and ₹ 100 crore for capex & other payments
- The company will be re-launching milk based beverages in CY21 as launch of the product in February 2020 was not successful due to the lockdown imposed in March 2020

Key Metrics






Exhibit 5: Volume growth to drive revenue 50.0 40.0 30.0 21.9 18.8

7.1 1.1 10.0 25 1.6 1.2 0.0 CY17 CY18 CY19 Y<mark>20E</mark> CY21E CY22E -10.0 -8.4-0.7 -20.0 Series1 Series2

Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research




Source: Company, ICICI Direct Research

Exhibit 8: Raw material to sales & EBITDA margins (%)

65.0 55.0 - 45.0 -	47.0	45.2	45.2	44.6	43.9	44.9
45.0 - 35.0 -						
25.0 -						
15.0 -	20.9	19.7	20.3	18.9	20.2	20.1
5.0 -		13.7	20.0	10.9	20.2	20.1
-5.0	CY17	CY18	CY19	CY20E	CY21E	CY22E

Raw material as % of sales EBITDA margin (%)

Exhibit 9: EBITDA (₹ crore) & EBITDA growth (%) trend



Source: Company, ICICI Direct Research







Exhibit 11: Return ratios to improve (%)



Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

Exhibit 12:	Valuation							
	Sales	Growth	EPS	Growth	PE	EV/EBITDA	RoNW	RoCE
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)
CY19	7129.6	39.7	16.4	-0.4	41.1	15.3	14.2	15.5
CY20E	6395.0	-10.3	11.3	-30.9	59.5	17.7	10.1	12.3
CY21E	7753.0	21.2	21.7	92.1	31.0	13.3	16.7	18.6
CY22E	8513.4	9.8	26.6	22.5	25.3	11.7	17.6	20.7

Financial summary

Exhibit 13: Profit and lo	ss statem	ient		₹ crore
	CY19	CY20E	CY21E	CY22E
Total operating Income	7129.6	6395.0	7753.0	8513.4
Growth (%)	39.7	-10.3	21.2	9.8
Raw Material Expenses	3219.4	2851.5	3401.2	3820.2
Employee Expenses	810.8	927.3	1007.9	1089.7
Marketing Expenses	122.1	65.4	118.8	129.2
Other expenses	1529.6	1342.0	1662.8	1765.0
Total Operating Expenditure	5681.9	5186.1	6190.7	6804.1
EBITDA	1,447.7	1,208.9	1,562.3	1,709.3
Growth (%)	43.8	-16.5	29.2	9.4
Depreciation	488.6	528.1	528.5	553.3
Interest	309.6	283.0	222.5	156.5
Other Income	42.5	36.9	40.5	44.6
PBT	691.9	434.7	851.8	1044.1
Total Tax	224.1	113.0	230.0	281.9
Minority interest	0.0	0.0	0.0	0.0
Profit from Associates	4.4	4.8	5.3	5.8
PAT	472.2	326.5	627.1	768.0
Growth (%)	57.5	-30.9	92.1	22.5
EPS (₹)	16.4	11.3	21.7	26.6

Source: Company, ICICI Direct Research

Exhibit 15: Balance she	et			₹ crore
(Year-end March)	CY19	CY20E	CY21E	CY22E
Liabilities				
Equity Capital	288.7	288.7	288.7	288.7
Reserve and Surplus	3039.7	2957.3	3459.0	4073.4
Total Shareholders funds	3328.4	3246.0	3747.7	4362.1
LT Borrowings & Provisions	2355.4	1955.4	1455.4	955.4
Deferred Tax Liability	282.5	296.6	311.5	327.0
Total Liabilities	6168.1	5677.7	5703.2	5842.7
Assets				
Gross Block	7,710.6	8,124.4	8,524.4	8,924.4
Less: Acc Depreciation	2,186.7	2,714.7	3,243.3	3,796.6
Net Block	5,892.5	5,409.7	5,281.1	5,127.8
Capital WIP	63.8	50.0	50.0	50.0
Net Intangible Assets	562.3	590.4	619.9	650.9
Non-current Investments	0.9	0.9	0.9	0.9
Goodwill	24.2	24.2	24.2	24.2
Current Assets				
Inventory	881.5	621.7	753.8	827.7
Debtors	172.6	159.9	193.8	212.8
Loans and Advances	6.9	177.6	215.4	236.5
Other Current Assets	219.8	14.2	17.2	18.9
Cash	171.1	306.8	344.0	552.7
Deferred Tax Assests	12.8	12.8	12.8	12.8
Current Liabilities				
Creditors	477.7	497.4	516.9	567.6
Provisions	30.0	53.3	64.6	70.9
Short term debt & other CL	1,697.5	1,433.0	1,559.3	1,586.1
Application of Funds	6,168.1	5,677.7	5,703.2	5,842.7

Source: Company, ICICI Direct Research

Exhibit 14: Cash flow state	ment			₹ crore
(Year-end March)	CY19	CY20E	CY21E	CY22E
Profit After Tax	907.7	604.6	844.3	918.7
Add: Depreciation	482.6	528.1	528.5	553.3
(Inc)/dec in Current Assets	-319.3	348.7	-244.5	-136.9
Inc/(dec) in CL and Provisions	234.1	-116.6	262.4	189.6
CF from operating activities	1,305.2	1,364.8	1,357.7	1,491.6
(Inc)/dec in Investments	73.1	0.0	0.0	0.0
(Inc)/dec in LT loans & advances	0.0	0.0	0.0	0.0
(Inc)/dec in Fixed Assets	-2,358.2	-405.9	-429.5	-431.0
Others	22.1	0.0	0.0	0.0
CF from investing activities	-2,319.2	-405.9	-429.5	-431.0
Issue/(Buy back) of Equity	900.2	0.0	0.0	0.0
Inc/(dec) in loan funds	648.7	-500.0	-600.0	-600.0
Dividend paid & dividend tax	-78.2	-65.3	-125.4	-153.6
Others	-317.5	-283.0	-222.5	-156.5
CF from financing activities	1,109.7	-856.3	-924.1	-885.1
Net Cash flow	95.7	102.7	4.1	175.5
Opening Cash	106.9	171.1	306.8	344.0
Other Bank balance	33.1	33.1	33.1	33.1
Closing Cash	171.1	306.8	344.0	552.7

Source: Company, ICICI Direct Research

Exhibit 16: Key ratios				₹ crore
(Year-end March)	CY19	CY20E	CY21E	CY22E
Per share data (₹)				
EPS	16.4	11.3	21.7	26.6
Cash EPS	33.3	29.6	40.0	45.8
BV	115.3	112.4	129.8	151.1
DPS	0.0	2.3	4.3	5.3
Cash Per Share	75.7	94.0	112.3	131.5
Operating Ratios (%)				
EBITDA Margin	20.3	18.9	20.2	20.1
PBT / Total Operating income	9.7	6.8	11.0	12.3
PAT Margin	6.6	5.1	8.1	9.0
Inventory days	45.1	35.5	35.5	35.5
Debtor days	8.8	9.1	9.1	9.1
Creditor days	24.5	28.4	24.3	24.3
Return Ratios (%)				
RoE	14.2	10.1	16.7	17.6
RoCE	15.5	12.3	18.6	20.7
Valuation Ratios (x)				
P/E	41.1	59.5	31.0	25.3
EV / EBITDA	15.3	17.7	13.3	11.7
EV / Net Sales	3.1	3.4	2.7	2.3
Market Cap / Sales	2.7	3.0	2.5	2.3
Price to Book Value	5.8	6.0	5.2	4.5
Solvency Ratios				
Debt/EBITDA	1.9	1.9	1.1	0.7
Debt / Equity	0.8	0.7	0.5	0.3
Current Ratio	0.6	0.6	0.6	0.6
Quick Ratio	0.1	0.2	0.2	0.2

Exhibit 17: ICICI Direct	cover	age u	nivers	e (FMC	CG)														
	CMP	TP		M Cap		EPS (₹)		P/E (x)			Price/Sales (x)			RoCE (%)				RoE (%)	
	(₹)	(₹)	Rating	(₹ Cr)	FY20	FY21E	FY22E	FY20	FY21E	FY22E	FY20	FY21E	FY22E	FY20	FY21E	FY22E	FY20	FY21E	FY22E
Colgate (COLPAL)	1,470	1,700	Buy	38,812	30.0	33.4	35.4	49.0	44.0	41.6	8.6	8.4	7.7	60.7	83.5	100.8	51.2	64.2	78.0
Dabur India (DABIND)	519	595	Buy	90,864	8.2	9.6	10.7	63.3	54.2	48.4	10.4	9.5	8.6	26.1	25.9	26.7	21.9	22.3	22.7
Hindustan Unilever (HINLEV)	2,061	2,500	Buy	510,548	31.2	32.4	38.8	66.1	63.6	53.1	13.3	12.0	10.4	89.5	24.5	28.5	85.7	18.6	21.9
ITC Limited (ITC)	169	250	Buy	218,801	12.5	11.7	13.0	13.6	14.4	13.0	4.7	4.6	4.1	29.4	28.3	36.1	23.8	21.7	27.7
Jyothy Lab (JYOLAB)	132	150	Hold	5,141	4.3	5.3	5.8	30.7	24.9	22.6	3.1	2.9	2.6	24.3	29.7	29.9	21.7	24.2	24.1
Marico (MARLIM)	371	440	Buy	46,834	8.1	8.8	9.5	45.9	42.1	38.9	6.4	6.2	5.6	41.0	42.3	45.1	34.5	36.3	38.5
Nestle (NESIND)	16,961	18,000	Hold	152,970	204.3	223.4	253.4	83.0	75.9	66.9	12.4	11.5	10.4	56.9	59.9	66.6	101.9	119.1	139.2
Tata Consumer Products (TATGLO	492	525	Buy	49,578	5.0	9.8	11.7	98.5	50.3	42.2	5.1	4.6	4.3	6.9	8.8	9.4	4.6	6.6	7.5
VST Industries (VSTIND)	3,400	3,850	Hold	5,307	196.9	206.0	211.9	17.3	16.5	16.0	4.3	4.5	4.2	52.1	45.3	46.1	38.6	33.6	34.2
Varun Beverage (VARBEV)	673	730	Hold	19,429	16.4	11.3	21.7	41.1	59.5	31.0	2.7	3.0	2.5	15.5	12.3	18.6	14.2	10.1	16.7
Zydus Wellness (ZYDWEL)	1,761	2,300	Buy	11,475	24.6	27.8	65.7	71.6	63.4	26.8	6.5	6.2	5.5	5.9	6.9	8.3	5.4	5.9	8.6

pankaj.pandey@icicisecurities.com

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15% Hold: -5% to 15%; Reduce: -15% to -5%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Sanjay Manyal, MBA (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report mont be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance. Investors are davised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.